Consequences to patients, clinicians, and manufacturers when very serious adverse drug reactions are identified (1997–2019): A qualitative analysis from the Southern Network on Adverse Reactions (SONAR)

Authors

C L. Bennett
S Hoque
N Olivieri
M A. Taylor
D Aboulafia
C Lubaczewski
A C. Bennett
J Vemula
B Schooley
B J. Witherspoon
A C. Godwin
P S. Ray
P R. Yarnold
H C. Ausdenmoore
M Fisherman
G Herring
A Ventrone
J Aldaco
W J. Hrushesky
J Restaino
H S. Thomsen
R Marx
C Migliorati
S Ruggiero
C Nabhan
K R. Carson
J M. McKoy
Y. Tony Yang, George Washington University
M W. Schoen
K Knopf
L Martin
O Sartor
S Rosen
W K. Smith

Document Type

Journal Article

Publication Date

1-2021

Journal

EClinicalMedicine

Volume

31

DOI

10.1016/j.eclinm.2020.100693

APA Citation

Bennett, C. L., Hoque, S., Olivieri, N., Taylor, M. A., Aboulafia, D., Lubaczewski, C., Bennett, A. C., Vemula, J., Schooley, B., Witherspoon, B. J., Godwin, A. C., Ray, P. S., Yarnold, P. R., Ausdenmoore, H. C., Fisherman, M., Herring, G., Ventrone, A., Aldaco, J., Hrushesky, W. J., Restaino, J., Thomsen, H. S., Marx, R., Migliorati, C., Ruggiero, S., Nabhan, C., Carson, K. R., McKoy, J. M., Yang, Y. T., Schoen, M. W., Knopf, K., Martin, L., Sartor, O., Rosen, S., & Smith, W. K. (2021). Consequences to patients, clinicians, and manufacturers when very serious adverse drug reactions are identified (1997–2019): A qualitative analysis from the Southern Network on Adverse Reactions (SONAR). EClinicalMedicine, 31 (). http://dx.doi.org/10.1016/j.eclinm.2020.100693

Peer Reviewed

1

Open Access

1